CSL Behring Submits C1-INH For Hereditary Angioedema
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
C1-esterase inhibitor joins Jerini's Firazyr and Lev's Cinryze in race to gain orphan exclusivity for acute HAE, and block other entrants
You may also be interested in...
Action Letter For Lev’s Cinryze Opens Window For Jerini To Hit Market First
Lev Pharmaceuticals received a "complete response" letter from FDA on its BLA for the C1-esterase inhibitor Cinryze for hereditary angioedema, giving German drug maker Jerini an opportunity to be first to market with a treatment for the orphan disease
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
Alzheimer’s, BRAIN Initiative Highlighted In $30 Billion NIH Budget Proposal
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.